role of factor xa inhibitors in cancer-associated thrombosis any new dataxa抑制剂的作用因素在癌症相关的血栓形成任何新的数据.pdf

Hindawi Publishing Corporation Advances in Hematology Volume 2011, Article ID 196135, 12 pages doi:10.1155/2011/196135 Review Article Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data? Ali Zalpour,1 Michael H. Kroll,2 Vahid Afshar-Kharghan,2 Syed Wamique Yusuf,3 and Carmen Escalante4 1 Pharmacy Clinical Programs, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 2 Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 3 Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 4 Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Correspondence should be addressed to Ali Zalpour, azalpour@ Received 21 July 2011; Revised 10 August 2011; Accepted 11 August 2011 Academic Editor: Shaji Kumar Copyright © 2011 Ali Zalpour et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The association between cancer and venous thromboembolism (VTE) has been well documented in the literature. Prevention and treatment of VTE in cancer patients is imperative. Typically, the mainstay regimen for VTE prevention and treatment has been anticoagulation therapy, unless contraindicated. This therapy consists of unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), factor Xa inhibitor, or vitamin K antagonist (VKA). Current guidelines recommend LMWH over VKA for the treatment of VTE in cancer patients. Factor-specific anticoagulants have been proven safe and effective, and recently factor